Brief: Immunotech Biopharm Says Jiaze Global Capital To Subscribe For New Convertible Bonds, Note
20/01/2026 15:18
Jan 20 (Reuters) - Immunotech Biopharm Ltd 6978.HK: JIAZE GLOBAL CAPITAL TO SUBSCRIBE FOR NEW CONVERTIBLE BONDS AND NOTE NEW CONVERTIBLE BONDS PRINCIPAL AMOUNT RMB270 MILLION PRINCIPAL AMOUNT OF NOTES RMB30 MILLION Further company coverage: 6978.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunotech Biopharm
See all newsBrief: Immunotech Biopharm Gets Approval In Sept 2025 For Clinical Translational Application Of Atl In Hainan
Brief: Immunotech Biopharm Receives Notice Of Rejection For Conditional New Drug Application For EAL Dated 27 April 2026
Brief: Trading In Shares Of Immunotech Biopharm Will Be Halted At 1:00 PM On April 28, HKEX Says
Brief: Immunotech Biopharm Posts Loss And Total Comprehensive Expense For Year Attributable Rmb230.8 Million
Brief: Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN